Thursday, March 21, 2013 7:02:58 PM
The trades went off way too quick in the last 15 minutes for it to be retail
Where does one come up with these theories?
"Retail" = people that are individual investors, daytraders - normal people sitting at home on their PC's (countless hundreds of thousands, if not millions of people), that have the capacity to click a single button on their keyboard to enter a trade. Thousands of clicks hitting within moments of one another, placing scores of trades at lightening speed = what happened today.
These rumors of Bricoleur being the ONLY firm that can push IGC stock around, are baseless and entirely off center when the fact remains that there is strength in numbers.
The last 15 minutes of trading was just that. Retail buys flooding in all at once, on the alerts of a very well respected and followed poster that has an incredible track record for choosing stocks that are about to make omminous moves.
Being up 40% or so, within moments, had me feeding the bidders some of my shares.
If a retracement comes, I will be there to reload shares.
If not, I will ride what i have and maybe even average up if IGC builds a higher and sustained level of support.
But yes, the action today was RETAIL, and that price/volume movement triggered technical indicators that would get ANY institutional investors attention. The key now, is FOLLOW THRU.
Again, your not going to see "news" issued by IGC (as many have eluded to be the cause of this move)
The "news" was that IGC was going to be featured in an SA article written by a prominent awareness promoter that has an excellent trackrecord for moving stocks.
Its just that simple.
Bricoleur had SQUAT to do with today's move.
"Bric" was blindsided by the twitterati just like the rest of the traders asking "hey, what the hell is going on with IGC?" - meanwhile they were clicking away lifting offers at a rapid pace IN CASE news hit.
No news
Just one guy thats alerting to a pending SA article.
Retail bought into it and THATS your volume.
End of story
Recent IGC News
- IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment • ACCESS Newswire • 05/19/2026 09:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:02:08 PM
- IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference • ACCESS Newswire • 05/15/2026 12:00:00 PM
- IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase • ACCESS Newswire • 04/28/2026 04:15:00 PM
- IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion • ACCESS Newswire • 04/22/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/20/2026 08:01:33 PM
- IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia • ACCESS Newswire • 04/20/2026 12:30:00 PM
- IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout • ACCESS Newswire • 04/14/2026 12:30:00 PM
- Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts • ACCESS Newswire • 04/08/2026 04:45:00 PM
- IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease • ACCESS Newswire • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:02:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:01:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:43:01 PM
- IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness • ACCESS Newswire • 03/30/2026 12:00:00 PM
- IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 • ACCESS Newswire • 03/19/2026 01:00:00 PM
- IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026 • ACCESS Newswire • 03/18/2026 01:00:00 PM
- IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research • ACCESS Newswire • 02/26/2026 01:30:00 PM
- IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets • ACCESS Newswire • 02/24/2026 01:30:00 PM
- IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial • ACCESS Newswire • 02/23/2026 01:30:00 PM
- IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances • ACCESS Newswire • 02/17/2026 01:30:00 PM
- IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets • ACCESS Newswire • 02/12/2026 01:30:00 PM
- IGC Pharma Announces Equity Research Update by Alliance Global Partners • ACCESS Newswire • 02/10/2026 01:30:00 PM
- IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center • ACCESS Newswire • 02/09/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 09:02:27 PM
